A Medical Preview of 2024 for Multiple Sclerosis and Related Disorders: Jiwon Oh, MD, PhD
February 11th 2024The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital shared thoughts on the promising advancements in the multiple sclerosis field for 2024. [WATCH TIME: 5 minutes]
BTK Inhibitor Clinical Development
November 6th 2023Patrick Vermersch, MD, PhD, and Krzysztof Selmaj, MD, PhD, provide an overview of the BTKi that are currently under investigation for MS, and Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, discusses what in vivo and in vitro preclinical work in models of MS have shown.
Where Tolebrutinib and Other BTK Inhibitors Fit in the MS Treatment Landscape: Jiwon Oh, MD, PhD
March 15th 2022The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed how investigational BTK inhibitors will be used among an ever-growing MS treatment toolbox. [WATCH TIME: 3 minutes]
Overview of Tolebrutinib’s Positive 18-Month Data in Relapsing MS: Jiwon Oh, MD, PhD
March 10th 2022The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the tolebrutinib’s mechanism of action, and new data presented at ACTRIMS Forum 2022. [WATCH TIME: 4 minutes]
The Need for Guidelines on the Management of Radiologically Isolated Syndrome: Jiwon Oh, MD, PhD
March 8th 2022The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed the lack of guidelines for patients with RIS and the research efforts needed going forward to establish them.